Adagene Inc
NASDAQ:ADAG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Adagene Inc
NASDAQ:ADAG
|
CN |
|
Microchip Technology Inc
NASDAQ:MCHP
|
US |
|
Godawari Power and Ispat Ltd
NSE:GPIL
|
IN |
|
Chain Bridge I
NASDAQ:CBRG
|
US |
|
Xos Inc
NASDAQ:XOS
|
US |
|
Future Consumer Ltd
NSE:FCONSUMER
|
IN |
|
Boe Varitronix Ltd
HKEX:710
|
HK |
|
B
|
BVZ Holding AG
SIX:BVZN
|
CH |
Adagene Inc
Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
